Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On January 5, 2023, Jaguar Health, Inc. (the "Company") received notice from the
Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC
("Nasdaq") indicating that, because the bid price for the Company's voting
common stock, par value $0.0001 per share (the "Common Stock"), had closed below
$0.10 per share for the preceding ten consecutive trading days, in contravention
of Nasdaq Listing Rule 5810(3)(A)(iii) (the "$0.10 Rule"), the Company's
securities were subject to delisting unless the Company timely requested a
hearing before the Nasdaq Hearings Panel (the "Panel") to appeal the Staff's
decision. The Company intends to timely request a hearing before the Panel,
which request will stay any further delisting action by Nasdaq at least pending
the Company's hearing and the expiration of any extension that the Panel may
grant to the Company following such hearing. There are no assurances that a stay
will be granted or that a favorable decision will be obtained.
Nasdaq previously granted the Company a 180-calendar grace period to regain
compliance with the minimum $1.00 bid price requirement set forth in Nasdaq
Listing Rule 5550(a)(2) (the "Bid Price Rule") through February 13, 2023.
At the Special Meeting of Stockholders of the Company scheduled for January 20,
2023, the Company will seek stockholder approval for the implementation of a
reverse stock split of the Company's issued and outstanding Common Stock at a
ratio of not less than 1-for-3 and not greater than 1-for-75, if deemed
advisable and at the Board's discretion to regain compliance with the Bid Price
Rule.
© Edgar Online, source Glimpses